Science & Innovation
We have been successfully manufacturing large molecule therapies for over two decades, and we take our responsibility of making and delivering quality medicine very seriously. In recent years, we have extended our expertise into the production of small molecule therapies and have fully integrated an oral solid dose facility into our manufacturing infrastructure.
We attribute our success to excellence in several key areas. Our process development team continually advances our understanding of the biology and process technology that are both critical to improving our capabilities and output. Our advanced engineering teams ensure our manufacturing plants are state of the art and equipped with cutting-edge technologies to meet the demand for our existing therapies, clinical trials and opportunities in biosimilars. Our world-class manufacturing teams are vital to the efficient and reliable operation of these assets. Our quality team manages compliance and supervises consistent and dependable production of our therapies, while our supply chain group works to make sure we are able to get our therapies to patients when and where they need them.
Thorough business continuity planning provides redundancy on a global level to ensure product availability. In addition, our teams create systems that reduce our impact on the environment by limiting waste and using resources efficiently. The combination of these skills enable us to manufacture and supply medicines to patients in more than 90 countries.
Biogen operates several manufacturing facilities around the world. Together, they total 198,000 liters of bioreactor capacity, one of the largest among biotech companies worldwide.